Laying the Foundation for Neuromuscular Disease Gene Therapy

Wang D , Tai PWL , Gao GP . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019; 18:358–378.

Keeler AM , Flotte TR . Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): where are we, and how did we get here?. Annu Rev Virol, 2019; 6:601–621.

Mendell JR , Al-Zaidy S , Shell R , et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.

Salami CO , Jackson K , Jose C , et al. Stress-induced mouse model of the cardiac manifestations of Friedreich's ataxia corrected by AAV-mediated gene therapy. Hum Gene Ther, 2020; 31:819–827.

Lind LA , Andel EM , McCall A , et al. Intralingual administration of AAVrh10-miR^SOD1 improves respiratory but not swallowing function in a SOD1 mouse model of ALS. Hum Gene Ther, 2020; 31:828–838.

Li J , Li Y , Wang J , et al. Defining transcription regulatory elements in the human frataxin gene: implications for gene therapy. Hum Gene Ther, 2020; 31:839–851.

Wilson JM , Flotte TR . Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther, 2020; 31:695–696.

Flotte TR . Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther, 2020; 31:398–399.

Pfizer. Pfizer's new phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study/default.aspx) (last accessed August 12, 2020 ).

Audentes Therapeutics. Statement from Audentes. https://www.joshuafrase.org/get-involved/recensus-study.php (last accessed August 12, 2020 ).